Pfizer and BioNTech Submit Data to EMA for Omicron BA.1 Adapted Bivalent Vaccine Candidate
Potential COVID-19 jab would apply to individuals age 12 and older
Pfizer and BioNTech have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted bivalent COVID-19 vaccine candidate, based on the BA.1 sub-lineage, for individuals 12 years of age and older.
The companies previously announced safety, tolerability, and immunogenicity data from a Phase 2/3 trial that found a 30 µg booster dose of the Omicron-adapted bivalent vaccine candidate produced a superior immune response against Omicron BA.1, as compared to the companies’ current COVID shot. The bivalent vaccine candidate was well-tolerated with a favorable safety profile.
The involved parties previously shared these data with FDA to support a potential variant-adapted vaccine, and they continue to submit additional data as advised by the agency.
Newron, Myung In Pharm Form Partnership Centered Around Treating Schizophrenia in South Korea
January 14th 2025The license agreement will feature an upcoming Phase III trial and—depending on results—the development, manufacturing, and commercialization of evenamide as a potential treatment option.
Machine Health in Pharmaceutical Production
December 2nd 2024Predictive maintenance in pharmaceutical production can help reduce downtime and increase efficiency. Grundfos Machine Health (GMH) uses artificial intelligence (AI)-driven wireless sensors to monitor motor health in real-time, identifying potential issues. This approach not only reduces maintenance costs but also ensures compliance with industry standards.
